Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? - Wikidata - awgldk - TriplyDB

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

http://www.wikidata.org/entity/Q53272044

about

Oligometastatic prostate cancer: Metastases-directed therapy?Update on positron emission tomography for imaging of prostate cancer Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.Molecular Imaging of Prostate Cancer Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatect Molecular and functional imaging of invasion and metastasis: windows into the metastatic cascade.Advanced imaging for the early diagnosis of local recurrence prostate cancer after radical prostatectomy.Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up.Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.Clinical Indications of C-Choline PET/CT in Prostate Cancer Patients with Biochemical Relapse.Controversies on individualized prostate cancer care: gaps in current practice.Translational Molecular Imaging of Prostate Cancer.Orthopaedic research in italy: state of the art.Non-FDG PET in oncology.Lymph Node Staging with Choline PET/CT in Patients with Prostate Cancer: A Review.PET-MR imaging using a tri-modality PET/CT-MR system with a dedicated shuttle in clinical routine.Advances in oncologic imaging: update on 5 common cancers.Serum tumor markers and PET/CT imaging for tumor recurrence detection.18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.11C-choline PET/CT and PSA kinetics.Choline PET/CT for imaging prostate cancer: an update.Individualized image-based lymph node irradiation for prostate cancer.A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.Imaging biomarkers in prostate cancer: role of PET/CT and MRI.Current use of PSMA-PET in prostate cancer management.New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography.Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.PET Tracers Beyond FDG in Prostate Cancer.11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer.PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.Sensitivity and specificity of PET/CT regarding the detection of lymph node metastases in prostate cancer recurrence.The Role of C-Choline-PET/CT-Guided Secondary Lymphadenectomy in Patients with PSA Failure after Radical Prostatectomy: Lessons Learned from Eight Cases.

P2860

Q26740069-AB824B30-7681-42E1-8384-1EE4F39CBD8C Q27026828-E3A3A67E-B5CE-41C0-99CC-2E38E4128844 Q28074669-C20B6C53-C950-45A6-B710-417560982268 Q31003607-3A8DD374-165C-4DC1-AE61-A9A3E8E73D1A Q31145236-74CF0325-91E3-4E76-ADFA-02ACE39AF73F Q33620520-141D4FE0-481D-425D-A30C-71CA01EE61B3 Q33767672-1643597D-CF7E-495D-8A0F-56ED8D781847 Q35064453-9C719E72-8B22-4A58-B791-EBE8999E3095 Q35155500-6FB6A3C6-D028-4152-A850-74556810F908 Q35604502-21C8F5F0-1E38-4759-9A8A-C8FC82292D72 Q35743289-3807751B-F712-4CF7-A447-0F92825CC51C Q35849174-2C647887-5BBE-441B-BA4E-CFC2A990C725 Q37149085-790A3DA1-AB0D-4BCB-9F56-FB85C9A05D8F Q37244969-3A5B24F5-7B5A-4EB1-AB5A-9CE5800064DE Q37888852-695A2370-6452-44AA-9A87-5CF28ECC71B3 Q37956045-AF87FD65-8610-424A-9C46-078B3925F6F2 Q37973351-E6F14641-476D-4999-AD5B-864A35CACC86 Q38051064-945BB8A3-389C-4891-9025-1A79839B5B2D Q38052458-BD7662B2-872F-45C8-8343-3741E78F3075 Q38082682-2A69A53D-C571-43DC-9244-29C7D715BB0C Q38098441-ABA5B338-D3CC-4DEA-A927-F9D2213171A1 Q38098442-99865E24-410A-4775-BC9F-C472CFB9C4FD Q38103180-85A74B0E-226A-410F-B7BC-B9ABF0066FB5 Q38109812-F08A21A5-B57B-48FD-A2B0-E77B710F012A Q38190115-E2749763-3C44-4B43-9254-58725FA329ED Q38321182-BC74992E-DEB5-406E-BFAE-9C06013698FB Q38744524-D3DF8B71-609D-47AF-B73F-8D14B2A402C4 Q38757513-670717B2-8D9A-4F09-991F-457B73CC16B2 Q38766102-4178F035-5286-4755-83C2-771F5361B81B Q38895102-D8A42810-6D91-4BF6-B06C-0C6A968933B8 Q39003086-0A3263CB-0747-4EF3-A851-B4DDA6EF9444 Q39176719-8EC31D03-DCDC-4F0C-A27A-AB8CE4EF632C Q39242140-6A19871E-CA1B-4EA7-A833-8BCD91DFADEA Q39293042-C96862B3-2575-49D4-8BF6-CB0ABAB92F5B Q39699773-241991B8-3BA1-4B88-B0F2-AA2E48F04299 Q39922053-0B4CBF2B-2B46-4EA9-A389-5F5CB13F32A4 Q41161118-2FD8343C-009C-49A7-BCD8-138D73A9AA72 Q41319390-ABD1067F-F980-4562-8362-A29A45142D04 Q41827640-A5CEBCCD-B4B1-407E-9111-F6290C36EE8F Q41860365-9D7FF338-4AFC-408A-9B3A-2D97B884D1FC

P2860

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

http://www.wikidata.org/entity/Q53272044

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Is there a role for ¹¹C-cholin ...... mild PSA increase <1.5 ng/ml?

@en

Is there a role for ¹¹C-cholin ...... mild PSA increase <1.5 ng/ml?

@nl

type

label

Is there a role for ¹¹C-cholin ...... mild PSA increase <1.5 ng/ml?

@en

Is there a role for ¹¹C-cholin ...... mild PSA increase <1.5 ng/ml?

@nl

prefLabel

Is there a role for ¹¹C-cholin ...... mild PSA increase <1.5 ng/ml?

@en

Is there a role for ¹¹C-cholin ...... mild PSA increase <1.5 ng/ml?

@nl

P1433

Q53272044-AEF97865-9732-4BBD-85A0-2C0683267178

P1476

Q53272044-3C11D4AC-F35B-4BF1-975F-B03D94CC1FBB

P2093

Q53272044-049A1771-723C-4EDE-9BA3-786D8905C25F

Q53272044-055D0B03-766A-4B3E-9782-728E64BA7A58

Q53272044-06910DDB-79F6-4229-83B3-A3F804475469

Q53272044-1C6DFA05-BBA4-4CE5-AB2B-F6859637A9AF

Q53272044-1CBDA15C-C5DA-42D5-A5A9-6EA3BE3BBB2D

Q53272044-25717A0E-3BAA-4A6B-B82F-55C9C9EB4EED

Q53272044-62E080D9-AEB7-4A21-A2A0-F284D786745E

Q53272044-8BB8858C-D30E-47E4-B74E-BD0F0C650843

Q53272044-A3FDF7D1-13B2-4526-8849-008A3213AE27

Q53272044-ABF1381F-C1E5-4DFA-AC9A-ADEE00E9303B

P2888

Q53272044-38A61DE3-6CF1-4A65-B4FE-1AB99948BCF0

P304

Q53272044-30D80DD3-A5A2-40BF-9B0F-FC0C7623AB68

P31

Q53272044-551C51BD-E652-43E0-A206-7423C9B81B98

P356

Q53272044-5F9A5C4E-0E65-4128-8BBB-6E6B4A00832D

P433

Q53272044-45F166EA-D4FD-4CB7-A1AB-0C6034F09108

P478

Q53272044-32AC0732-736F-4E5E-8BA8-142BF4A87892

P50

Q53272044-B6876438-4EEA-4FEB-BDC9-042F3BFBEE25

P577

Q53272044-AD619752-E024-411B-A515-B864CD2194D6

P698

Q53272044-64CFF536-DF35-4E8D-89FD-306BE6AC8C97

P921

Q53272044-DBCFCFAE-DBB6-4570-AC7D-4D250ADF2651

P356

S00259-010-1604-0

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Is there a role for ¹¹C-cholin ...... mild PSA increase <1.5 ng/ml?

@en

P2093

Chiara Fuccio

http://www.w3.org/2001/XMLSchema#string

Cristina Nanni

http://www.w3.org/2001/XMLSchema#string

Domenico Rubello

http://www.w3.org/2001/XMLSchema#string

Gian Carlo Montini

http://www.w3.org/2001/XMLSchema#string

Giuseppe Martorana

http://www.w3.org/2001/XMLSchema#string

Ivan Santi

http://www.w3.org/2001/XMLSchema#string

Maria Cristina Marzola

http://www.w3.org/2001/XMLSchema#string

Paolo Castellucci

http://www.w3.org/2001/XMLSchema#string

Riccardo Schiavina

http://www.w3.org/2001/XMLSchema#string

Stefano Boschi

http://www.w3.org/2001/XMLSchema#string

P2888

s00259-010-1604-0

P304

55-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-010-1604-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P50

Valentina Ambrosini

P577

2010-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20848281

http://www.w3.org/2001/XMLSchema#string

P921